Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study.
Jun XieHanxu GuoBaijun DongWei ChenChengqi JinQiufan XuLi DingWujianhong LiuShengrong DongTingting ZhaoYang YuChangcheng GuoXudong YaoBo PengBin YangPublished in: European urology oncology (2024)
Our study shows that the drug combination of olaparib plus abiraterone improved survival over abiraterone alone for patients who have mutations in genes affecting DNA repair and metastatic prostate cancer resistant to hormone therapy. The results provide evidence of a synergistic effect of the two drugs in these patients.
Keyphrases
- dna damage
- dna repair
- prostate cancer
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- squamous cell carcinoma
- prognostic factors
- small cell lung cancer
- oxidative stress
- emergency department
- stem cells
- drug delivery
- clinical trial
- randomized controlled trial
- cancer therapy
- mesenchymal stem cells
- genome wide
- cell therapy
- combination therapy